Multiple Myeloma | Specialty

OncLive News Network On Location: In Chicago Saturday, June 1

June 2nd 2019

FDA Grants Frontline Daratumumab Regimen Priority Review in Transplant-Eligible Myeloma

May 31st 2019

The FDA has granted a priority review designation to a supplemental biologics license application for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Navigating the Complex Treatment Paradigm of Relapsed/Refractory Multiple Myeloma

May 31st 2019

Cristina Gasparetto, MD, discusses the rapidly evolving field of relapsed/refractory myeloma.

Dr. Bianchi on Maintenance Therapy in Multiple Myeloma

May 24th 2019

Giada Bianchi, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses maintenance therapy in the treatment of patients with multiple myeloma.

Dr. Hari on Current State of Frontline Therapy in Myeloma

May 23rd 2019

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the current state of frontline therapy in multiple myeloma.

Dr. Richardson on Immunotherapy Advances in Relapsed/Refractory Myeloma

May 22nd 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses advances made with immunotherapy in the treatment of patients with relapsed/refractory multiple myeloma.

EU Approves Lenalidomide- and Pomalidomide-Based Triplets for Myeloma

May 16th 2019

The European Commission has granted an approval to lenalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for stem cell transplant, as well as pomalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with myeloma who have received ≥1 prior treatment regimen that included lenalidomide.

Lenalidomide Reduces Risk for Smoldering Multiple Myeloma Progression

May 16th 2019

In patients with smoldering multiple myeloma, lenalidomide induced a 72% reduction in the risk for progression to symptomatic disease at 3 years.

Dr. Chhabra on Impactful Advances in Relapsed/Refractory Multiple Myeloma

May 15th 2019

Saurabh Chhabra, MD, MS, assistant professor at the Medical College of Wisconsin, discusses the most impactful advances made in relapsed/refractory multiple myeloma.

FDA Grants P-BCMA-101 CAR T-Cell Therapy Orphan Drug Designation for Myeloma

May 14th 2019

The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Hari Discusses the Role of MRD in Myeloma

May 8th 2019

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease in myeloma.

Frontline Advances Propel Progress in Multiple Myeloma

May 7th 2019

Parameswaran Hari, MD, MRCP, discusses the rapidly evolving paradigm of myeloma with a focus on the latest updates in the frontline setting.

Emerging Agents Spur Optimism in Myeloma

May 7th 2019

Saurabh Chhabra, MD, MS, highlights emerging agents in the field of relapsed/refractory myeloma that have oncologists optimistic for the future.

Large Myeloma Study Aims to Analyze Multiple Regimens

May 6th 2019

Therapy for patients with multiple myeloma encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan.

Dr. Dhakal on Early Data With BiTEs in Multiple Myeloma

May 3rd 2019

Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.

Dr. Bianchi on Shifting Landscape of Transplant Eligible Myeloma

April 30th 2019

Giada Bianchi, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses treatment options for transplant eligible patients with multiple myeloma.

Dr. Richardson on Treatment Approaches Targeting Mutational Burden in Myeloma

April 23rd 2019

Paul G. Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine, Harvard Medical School, discusses treatment approaches targeting mutational burden in multiple myeloma.

Sequencing Challenges Emerge in Myeloma as Options Expand

April 22nd 2019

Omar Nadeem, MD, highlights exciting approaches that have emerged in relapsed/refractory myeloma, such as CAR T-cell therapy, and shares unanswered questions that future research should address.

Monoclonal Antibodies Shake Up Myeloma Paradigm

April 22nd 2019

Paul G. Richardson, MD, highlights the many promising agents that have emerged in relapsed/refractory multiple myeloma in recent years, remaining challenges, and hope for continued progress.

Frontline Approaches Focus on Depth of Response in Newly Diagnosed Myeloma

April 19th 2019

Giada Bianchi, MD, discusses the scope of frontline therapy and subsequent maintenance strategies among patients with transplant eligible and ineligible newly diagnosed multiple myeloma.